enGene reports Cohort 1 LEGEND data and FDA alignment; CG Oncology awaits PIVOT-006 readout
enGene said it aligned with FDA on BLA components after pivotal Cohort 1 results, while CG Oncology still expects PIVOT-006 topline data in November 2026.
SEC filing (3)